Characterization of tirzepatide-treated patients achieving different categorical measures of weight loss in SURPASS 1-4

被引：0
|
作者：
Batterham, R. [1 ]
Malecki, M. [2 ]
Sattar, N. [3 ]
Lee, C. [4 ]
Rodriguez, A. [4 ]
Bergman, B. [4 ]
Wang, H. [5 ]
Ghimpeteanu, G. [4 ]
Levine, J. [4 ]
机构：
[1] UCL, Dept Med, London, England
[2] Jagiellonian Univ Med Coll, Dept Metab Dis, Krakow, Poland
[3] Univ Glasgow, Inst Cardiovasc & Med Sci, BHF Glasgow Cardiovasc Res Ctr, Glasgow, Lanark, Scotland
[4] Eli Lilly & Co, Diabet, Indianapolis, IN 46285 USA
[5] TechData Serv Co, Stat, King Of Prussia, PA USA
来源：
DIABETES RESEARCH AND CLINICAL PRACTICE | 2023年 / 197卷
关键词：
D O I：
10.1016/j.diabres.2023.110303
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
IDF2022-03
引用
收藏
页数：1
相关论文
共 19 条
  • [1] Characterization of Tirzepatide-Treated patients achieving HbA1c <5.7% in the SURPASS 1-4 Trials
    Rosenstock, Julio
    Del Prato, Stefano
    Franco, Denise R.
    Vazquez, Luis A.
    Dai, Biyue
    Weerakkody, Govinda J.
    Lando, Laura Fernandez
    Rodriguez, Angel
    Bergman, Brandon
    DIABETES, 2022, 71
  • [2] Characterization of tirzepatide-treated patients achieving HbA1c <5.7% in the SURPASS 1-4 trials
    Rosenstock, Julio
    Del Prato, Stefano
    Franco, Denise Reis
    Vazquez, Luis
    Dai, Biyue
    Weerakkody, Govinda
    Fernandez-Lando, Laura
    Rodriguez, Angel
    Bergman, Brandon K.
    Chen, Xi
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2024, 153
  • [3] Characterization of tirzepatide-treated patients achieving different glycemic control levels in SURPASS-AP-Combo
    Bao, Yuqian
    Han, Lin
    Du, Liying
    Ji, Linong
    OBESITY, 2024, 32 (06) : 1102 - 1113
  • [4] Predictors of achieving weight loss ≥15% with tirzepatide in people with type 2 diabetes from SURPASS 1-4
    Malecki, M.
    Batterham, R.
    Sattar, N.
    Levine, J.
    Rodriguez, A.
    Bergman, B.
    Wang, H.
    Ghimpeteanu, G.
    Lee, C.
    DIABETES RESEARCH AND CLINICAL PRACTICE, 2023, 197
  • [5] Achieving Normoglycemia With Tirzepatide: Analysis of SURPASS 1-4 Trials
    Rosenstock, Julio
    Vazquez, Luis
    Del Prato, Stefano
    Franco, Denise Reis
    Weerakkody, Govinda
    Dai, Biyue
    Lando, Laura Fernandez
    Bergman, Brandon K.
    Rodriguez, Angel
    DIABETES CARE, 2023, 46 (11) : 1986 - 1992
  • [6] Changes in liver and abdominal fat in tirzepatide-treated patients achieving normoglycaemia in the SURPASS-3 MRI substudy
    Rodriguez, A.
    Cusi, K.
    Gastaldelli, A.
    Nicolay, C.
    Torcello-Gomez, A.
    Lando, L. Fernandez
    DIABETOLOGIA, 2023, 66 (SUPPL 1) : S333 - S333
  • [7] Changes in Liver and Abdominal Fat in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 MRI Substudy
    Rodriguez, Angel
    Cusi, Kenneth
    Gastaldelli, Amalia
    Nicolay, Claudia
    Torcello-Gomez, Amelia
    Lando, Laura Fernandez
    DIABETES, 2023, 72
  • [8] PROs in Tirzepatide-Treated Adults with Type 2 Diabetes in SURPASS-1 to-6 by Age, Gender, BMI, and Weight Loss
    Boye, Kristina
    Thieu, Vivian
    Dong, Wenxiu
    Williamson, Suzanne E.
    Sapin, Helene
    DIABETES, 2024, 73
  • [9] Time in Range and Time in Tight Range in Tirzepatide-Treated Patients Achieving Normoglycemia in the SURPASS-3 CGM Substudy
    Bergenstal, Richard M.
    Rodriguez, Angel
    Benneyworth, Brian D.
    Nicolay, Claudia
    Brown, Katelyn
    DIABETES, 2023, 72
  • [10] Early Weight Loss and Cardiometabolic Parameters in Tirzepatide-Treated Participants in SURMOUNT 1-2
    Thethi, Tina
    Kokkinos, Alexander
    McKean-Matthews, Missy
    Lee, Clare
    Neff, Lisa
    Mast, Casey
    Rodriguez, Angel
    Stefanski, Adam
    Bartee, Amy
    OBESITY, 2024, 32 : 34 - 34
12